Harvard Bioscience Inc - Asset Resilience Ratio
Harvard Bioscience Inc (HBIO) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Harvard Bioscience Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2017)
This chart shows how Harvard Bioscience Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Harvard Bioscience Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Harvard Bioscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Harvard Bioscience Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Harvard Bioscience Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Harvard Bioscience Inc Industry Peers by Asset Resilience Ratio
Compare Harvard Bioscience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Tinavi Medical Technologies Co Ltd
SHG:688277 |
Medical Instruments & Supplies | 2.05% |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK |
Medical Instruments & Supplies | 6.64% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
Daxor Corporation
NASDAQ:DXR |
Medical Instruments & Supplies | 65.10% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Annual Asset Resilience Ratio for Harvard Bioscience Inc (2011–2017)
The table below shows the annual Asset Resilience Ratio data for Harvard Bioscience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $109.35 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $107.77 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $120.22 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $135.92 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $135.46 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $133.48 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $126.63 Million | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more